# Vivani Medical, Inc.: overview VANI · Nasdaq · CIK 1266806 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/vani.md) · [Financials](/companies/vani/financials.md) · [Filings](/companies/vani/filings.md) · [Insiders](/companies/vani/insiders.md) Latest reported revenue: [$0](/filings/0001753926-25-001330.md) for Q2 FY2025, three months to 2025-06-30, from the 10-Q filed Aug 13, 2025 (XBRL us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax, accession 0001753926-25-001330). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [0.0 d](/filings/0001753926-24-001874.md) | [0.0 d](/filings/0001753926-25-000527.md) | [0.0](/filings/0001753926-25-000794.md) | [0.0 d](/filings/0001753926-25-001330.md) | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.11)](/filings/0001753926-25-001770.md) | not reported | [(0.11)](/filings/0001753926-26-000852.md) | [(0.12)](/filings/0001753926-26-001477.md) | [(0.11)](/filings/0001753926-25-001770.md) | not reported | [(0.08)](/filings/0001753926-26-000852.md) | [(0.07)](/filings/0001753926-26-001477.md) | | Free cash flow | $k | [(5,702) d](/filings/0001753926-25-001770.md) | [(6,108) d](/filings/0001753926-26-000548.md) | [(5,168)](/filings/0001753926-26-000852.md) | [(6,158) d](/filings/0001753926-26-001477.md) | [(7,174) d](/filings/0001753926-25-001770.md) | [(6,993) d](/filings/0001753926-26-000548.md) | [(6,199)](/filings/0001753926-26-000852.md) | [(6,134) d](/filings/0001753926-26-001477.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | [0.0](/filings/0001753926-25-000527.md) | [0.0](/filings/0001753926-26-000548.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.27)](/filings/0001753926-22-000356.md) | not reported | [(0.50)](/filings/0001753926-25-000527.md) | [(0.43)](/filings/0001753926-26-000548.md) | [(0.43)](/filings/0001753926-26-000548.md) | | Free cash flow | $m | [(11.5)](/filings/0001753926-23-000344.md) | [(19.1)](/filings/0001753926-24-000616.md) | [(24.6)](/filings/0001753926-25-000527.md) | [(21.3)](/filings/0001753926-26-000548.md) | [(25.5)](/filings/0001753926-26-000548.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareBasicAndDiluted; Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/vani/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $2.2m | 1,768,077 | | Added +237,144 | | [Tanager Wealth Management LLP](/funds/1892929.md) | 2026-06-30 | $753.0k | 607,276 | | Reduced −33,809 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $728.9k | 587,745 | | Reduced −12,833 | | [TUDOR INVESTMENT CORP ET AL](/funds/923093.md) | 2026-06-30 | $509.5k | 410,902 | | Reduced −15,400 | | [COMMONWEALTH EQUITY SERVICES, LLC](/funds/312272.md) | 2026-06-30 | $409.9k | 330,565 | | Unchanged | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $403.6k | 325,462 | | Added +61,631 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $374.3k | 301,828 | | Added +4,330 | | [MONETARY MANAGEMENT GROUP INC](/funds/1133014.md) | 2026-06-30 | $240.5k | 193,977 | | Unchanged | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $192.2k | 154,965 | | Unchanged | | [NORTHERN TRUST CORP](/funds/73124.md) | 2026-06-30 | $145.0k | 116,907 | | Added +20,446 | ## Recent filings [All 835 filings](/companies/vani/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-30 | 16:30 ET | [8-K](/filings/0001753926-26-002036.md) | 7.01 Regulation FD disclosure | 0001753926-26-002036 | | 2026-10-29 | 07:30 ET | [8-K](/filings/0001753926-26-002024.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001753926-26-002024 | | 2026-09-16 | 16:15 ET | [8-K](/filings/0001753926-26-001808.md) | 7.01 Regulation FD disclosure | 0001753926-26-001808 | | 2026-08-17 | 08:00 ET | [8-K](/filings/0001753926-26-001536.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001753926-26-001536 | | 2026-08-13 | 16:31 ET | [8-K](/filings/0001753926-26-001482.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001753926-26-001482 | | 2026-08-13 | 16:01 ET | [10-Q](/filings/0001753926-26-001477.md) | Quarterly report, period 2026-06-30 | 0001753926-26-001477 | | 2026-08-06 | 08:15 ET | [8-K](/filings/0001753926-26-001349.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001753926-26-001349 | | 2026-07-16 | 08:30 ET | [8-K](/filings/0001753926-26-001190.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001753926-26-001190 | | 2026-07-07 | 07:46 ET | [8-K](/filings/0001753926-26-001144.md) | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001753926-26-001144 | | 2026-06-30 | 08:03 ET | [8-K](/filings/0001753926-26-001109.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 8.01 Other events; 9.01 Financial statements and exhibits | 0001753926-26-001109 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001753926-26-000548.md), filed Mar 26, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1266806 - Tickers: VANI - Exchange: Nasdaq - SIC code: 3845 Electromedical & Electrotherapeutic Apparatus - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 30, 2026, 16:40 ET. No prices; not investment advice.